Back To Top

Corestem inks W13b deal with Hanlim Pharm

[DISCLOSURE] Corestem (166480) has clinched a technology transfer deal worth 13 billion won (US$11.4 million) with Hanlim Pharm on a stem cell treatment for systemic lupus erythematosus, it said on July 26. The deal amounts to 19.4 percent of Corestem’s recent net worth.
MOST POPULAR
LATEST NEWS
subscribe
피터빈트